other material
confidence high
sentiment positive
materiality 0.80
Intellia reports new Phase 1 data for NTLA-2001: median TTR reduction 91%, 55mg dose selected for Phase 3
Intellia Therapeutics, Inc.
- Median serum TTR reduction of 91% and median residual TTR of 17 µg/mL at day 28 across 62 patients (doses ≥0.3 mg/kg).
- 29 patients with ≥12 months follow-up show sustained TTR reduction; no loss of activity over time.
- NTLA-2001 generally well tolerated; infusion-related reactions in 38% (mostly Grade 1-2); no dose-limiting toxicities.
- 55 mg fixed dose selected for global pivotal Phase 3 trial, expected to begin by year-end 2023; FDA IND clearance received.